Restoration Hardware Holdings Inc
Latest Restoration Hardware Holdings Inc News and Updates
Why Danaher Stock Rose after Its 4Q16 Results
Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.
AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016
On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.
AstraZeneca’s Tagrisso Had a Strong Commercial Launch in 2016
After its commercial launch in 41 countries, AstraZeneca’s Tagrisso has witnessed a solid uptake, earning revenues of $276.0 million in 2016 YTD.
Loss of Patent Protection to Drag Pfizer’s Top Line
With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010.
Bristol’s Opdivo Has One Eye on Advanced Bladder Cancer
After its 3Q16 earnings, there were multiple positive triggers for Bristol-Myers Squibb (BMY) stock.
Xalkori Label Expansion May Boost Pfizer’s Sales in 2016
On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.
Keytruda Leads over Opdivo in Head and Neck Cancer Treatment
CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in January 2016. The drug is under priority review by the FDA with an action date set for November 11, 2016. With similar approved indications, Opdivo and Merck’s (MRK) […]
2016’s Estimated Product Launches: LixiLan, Sarilumab, Lixisenatide
LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug.
What Made Cepheid Attractive to Danaher?
On September 6, 2016, Danaher (DHR) announced that it has entered into a definitive agreement to acquire Cepheid (CPHD) for $4 billion.
How Danaher Diagnostics Fares against Its Competition
Danaher’s Diagnostics unit had operating margins of 15.4% in 2015 and 17.2% in 1H16.
The Key Product Lines That Make Up Danaher’s Diagnostics Business
Danaher’s (DHR) Diagnostics unit, established through the acquisition of Radiometer in 2004, earned $4.9 billion in sales in 2015.
Understanding the Skeleton of Danaher’s Life Sciences Business
Customers in the Danaher life sciences business generally look at how the technology offered by a company can fit into their workflows.
Regeneron’s Robust Pipeline
Regeneron’s (REGN) robust pipeline consists of 13 molecules in various phases of development. Sarilumab is under review with the FDA.
How Are Drugs Priced in Japan?
The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.
Decoding Roche’s Performance on EV-to-EBITDA Basis
As of March 8, Roche Holding was trading at a forward EV-to-EBITDA multiple of 9.73x—a discount compared to Bristol-Myers Squibb’s 16.09x.
AbbVie’s Late-Stage Research Pipeline Could Boost Future Revenues
In partnership with Bristol-Myers Squibb, AbbVie is exploring elotuzumab to treat relapsed refractory multiple myeloma. The drug also received a breakthrough therapy designation from the FDA on May 19, 2014.
Abraxane Sales Are Lower than Expected in 3Q15
Abraxane’s sales in the US market fell by 4.2% from 3Q14 to 3Q15, while its sales in the rest of the world’s markets rose by 39.7% in the same time period.
Biogen’s Collaborative Arrangements See Strong Development in 3Q15
In 3Q15, Biogen saw several positive developments for the drugs developed under its various collaborative arrangements.
Novo Nordisk: Core Capabilities Differentiate It from Competition
Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically.
Amgen’s Presence in the Biosimilar Market
As it is still relatively difficult to introduce biosimilars, Amgen plans to enter the US market by leveraging experience of biosimilars in the European market.
An Overview of Regeneron’s Business Model
Regeneron generates revenues in three ways: product sales, revenues earned through collaboration arrangements, and revenues earned from licensing proprietary technology.
Patents and the Biotechnology Sector
The biotechnology industry will witness 12 blockbuster drugs worth $67 billion in annual revenues lose their patents by 2020. This is the so-called patent cliff.
